Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | TOP1 | P11387 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565103 | 0.88 | KDM4E (0.63) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL12665508 | 0.86 | KDM4E (0.67) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL12637996 | 0.86 | KDM4E (0.94) | KDM4ETOP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10566403 | 0.85 | KDM4E (0.54) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL7497840 | 0.85 | KDM4E (0.54) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL9088310 | 0.85 | KDM4E (0.54) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL12638277 | 0.85 | KDM4E (0.82) | KDM4ETOP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12665509 | 0.85 | KDM4E (0.64) | KDM4ETOP1KMT2AALDH1A1HPGD | |
| SCHEMBL2088723 | 0.85 | KDM4E (0.54) | KDM4EKMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL9534790 | 0.85 | KDM4E (0.54) | KDM4ETOP1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| US-5990122-A | SUBSTITUTED IN THE 7-POSITION BY A TRICYCLIC AMINE RADICAL; REDUCED GENOTOXIC PROPERTIES AND INCREASED ANTIBACTERIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| US-5986105-A | ENANTIOMORPHS AS BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5605910-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5508278-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0259804-B1 | Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process | HOFFMANN LA ROCHE (CH) | 1993-11-18 | — | — | EP | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-4864023-A | MICROBIOCIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4801584-A | ANTIMICROBIAL | HOFFMANN-LA ROCHE INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0259804-A2 | Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | KDM4E 1947/4885TOP1 160/4885KMT2A 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.